Researchers have used overlapping peptide libraries, amino acid substitutions, T-cell assays, structural analysis, and tolerance experiments to investigate different parts of the autoimmune response. The studies do not produce one uniform pattern. Results vary with the peptide, MHC background, T-cell population, and experimental model.
Autoimmune Peptide Epitopes
Defined Self-Antigen Peptides
Researchers have identified autoimmune peptide epitopes by testing sequences taken from larger self-antigens. In a murine lupus study, 145 overlapping peptides spanning all four core nucleosomal histones were tested. Three regions, H2B(10-33), H4(16-39), and H4(71-94), contained epitopes recognized by pathogenic T-helper cells. The identified peptides also stimulated those cells in vivo in the lupus model.
MOG studies used a different mapping strategy. Researchers examined overlapping peptides covering the complete 218-amino-acid MOG sequence rather than focusing only on MOG(35-55). This identified MOG(119-132), MOG(181-195) and MOG(186-200) as additional T-cell determinants. A separate study independently identified MOG(113-127), MOG(120-134), and MOG(183-197) after testing overlapping sequences from MOG.
Human lupus research also identified recurrent histone peptide targets. CD4 T cells from patients recognized H2B(10-33), H4(16-39), H4(71-94) and H3(91-105), with additional responses directed toward H2A(34-48) and H4(49-63).
Immunodominant Peptide Sequences
Immunodominance was examined by comparing responses to different sequences rather than treating every peptide from an antigen as equivalent.
In the full-length MOG study, MOG(119-132) generated a significantly higher frequency of responding T cells than MOG(35-55) after immunization with intact MOG in C57BL/6 mice. The investigators therefore identified MOG(119-132) as an immunodominant encephalitogenic determinant in that experimental setting. Its activity was also dependent on the H-2 background because the same peptide did not produce EAE in several non-H-2^b strains.
Nucleosomal studies produced another example. Scanning overlapping peptides and examining naturally processed material identified five major histone epitopes: H1'(22-42), H2B(10-33), H3(85-105), H4(16-39) and H4(71-94). These sequences were recognized by lupus T cells and B cells, with presentation observed across several MHC alleles.
The human lupus study also found differences between peptide responses. H4(16-39), H4(71-94), and H3(91-105) produced stronger IFN-Ξ³ responses, whereas H2A(34-48) favored IL-10 and/or IL-4 responses in the tested samples.
Peptide-MHC-TCR Recognition
MHC-Binding Residues
Researchers have experimentally separated residues involved in peptide binding to MHC from positions that primarily affect T-cell recognition.
For MOG (38-51), substitution experiments identified Y40 as the dominant MHC binding residue for I-A^b. Replacing Y40 with alanine reduced binding by approximately 50%. The study therefore linked this position specifically to peptide accommodation within the MHC molecule.
PLP(139-151) produced a separate residue map. Experiments using six PLP-specific T-cell clones identified L145 and P148 as important for I-A^s binding. The same study identified W144 and H147 as TCR-binding positions, providing an experimental distinction between the two types of contact.
A separate PLP investigation used alanine-substituted peptides and similarly found that L141 and P148 were consistent with MHC-binding positions, while W144 and H147 were associated with TCR contact.
TCR Contact Residues
TCR recognition was examined by measuring how individual substitutions changed T-cell activation while retaining peptide-MHC binding.
In the MOG(38-51) experiments, replacing R41, F44, R46, or V47 with alanine abolished T-cell responses without reducing affinity for I-A^b. G38 and W39 produced smaller effects. These results identified R41, F44, R46, and V47 as major TCR-contact residues in that peptide-MHC system.
Structural research provided a separate examination of TCR recognition. A crystal structure of autoimmune TCR 3A6 bound to MBP peptide and HLA-DR2a showed that the receptor primarily contacted the N-terminal portion of the MBP peptide. The interface contained relatively few hydrogen bonds between the receptor and peptide, and binding produced conformational changes within the peptide-MHC complex.
A structural comparison involving five autoimmune TCR-peptide-MHC complexes also found different docking arrangements among self-reactive receptors. The study compared the positions of TCR complementarity-determining regions across the complexes rather than assigning one universal binding geometry to autoimmune TCRs.
Altered Peptide Ligands
Single-Residue Peptide Changes
Altered peptide ligand experiments change selected amino acids within an antigenic sequence and then compare the modified peptide with the original sequence.
The PLP(139-151) Q144 study replaced tryptophan at position 144 with glutamine. The resulting Q144 sequence was therefore identical to the native peptide except for that single substitution. Researchers then examined the immune response generated by the modified sequence in the EAE model.
Another PLP study examined several peptide analogues containing substitutions around positions 144 and 147. The investigators compared these modified sequences with the native PLP (139-151) peptide to determine how individual residue changes affected biological activity.
This experimental design allows researchers to associate a measured change in T-cell behavior with a defined sequence alteration rather than changing the entire antigen.
Different T-Cell Responses to Altered Ligands
The response to an altered sequence can differ from the response to the corresponding native peptide.
The Q144 PLP ligand produced CD4 T-cell responses despite replacing the native W144 residue. A later study found that altered PLP peptides could generate different proliferative responses and cytokine profiles after single-residue substitution.
The response could also differ between T-cell populations. Research comparing PLP-specific Th1 and Th2 clones found that Th1 cells depended strongly on W144, whereas the Th2 clones examined after Q144 exposure used L141/G142 as their major contact region and tolerated substitution at position 144.
Structural research with autoimmune TCR 3A6 provides another example. Substitutions in peptide positions directed toward the TCR produced substantially different proliferative responses, demonstrating that closely related peptide ligands can behave differently within the same receptor-MHC system.
Epitope Spreading in Autoimmune Models
Expansion of Autoimmune Peptide Targets
Epitope spreading studies examine whether additional self peptide targets become recognized after an autoimmune response has already begun.
In SJL mice with relapsing EAE, researchers found that an initial response involving PLP(139-151) was followed by responses to the separate PLP(178-191) determinant. The secondary response was detected through T-cell proliferation and delayed-type hypersensitivity measurements.
Another experiment showed a different form of spreading. EAE initiated with MBP produced later responses against PLP(139-151) during active disease. That response was not observed in the passive EAE model used in the same investigation.
A subsequent study identified PLP(178-191)-specific T cells during relapsing EAE initiated with PLP(139-151) and found that these cells could transfer disease to naive recipients.
Changing Antigenic Specificity
The studies show that the set of recognized self-determinants can change during an experimental autoimmune response.
In PLP-induced relapsing EAE, responses to the secondary PLP(178-191) determinant appeared after the initial PLP(139-151)-associated response. The researchers linked the emergence of the secondary population with tissue damage during the acute phase.
The MBP model produced a different pattern. Active EAE initiated with MBP developed a response to PLP(139-151), whereas passive EAE did not show the same intermolecular spreading. This difference demonstrates that the route used to establish the experimental response affected the later antigenic repertoire.
Research in two CNS demyelinating models further localized the activation of newly responding PLP(139-151)-specific T cells to the CNS. In those experiments, CNS dendritic cells efficiently presented endogenous antigen to naive T cells.
Antigen-Specific Immune Tolerance
Tolerance to Defined Peptide Epitopes
Tolerance experiments have used defined self-peptides to examine changes in antigen-specific immune responses in autoimmune models.
In lupus-prone SNF1 mice, researchers administered very low doses of nucleosomal histone peptides at two-week intervals. H4(71-94) produced the strongest response among the tested autoepitopes. The experiment identified CD4+CD25+ and CD8+ regulatory T-cell populations containing autoantigen-specific cells.
A separate lupus study examined H2B(10-33), H4(16-39) and H4(71-94). Peptide exposure was followed by measurements of autoimmune T-cell help and autoantibody production. The investigators reported that tolerization with individual nucleosomal peptides affected pathogenic immune responses despite different peptides being used.
Another experiment used palmitoylated PLP peptides, including PLP (139-151) and PLP (178-191), to investigate tolerance in SJL mice. The study measured lymphocyte proliferation and responses during acute and relapsing EAE.
Changes in Antigen-Specific Responses
The measured effects differed between tolerance models.
In the SNF1 study, low-dose H4(71-94) exposure generated regulatory T-cell populations capable of suppressing IFN-Ξ³ responses from pathogenic lupus T cells responding to nucleosomal epitopes. The investigators also measured substantial reductions in autoantibody production.
The earlier nucleosomal-peptide study found impaired autoimmune T-cell help after tolerization. Production of multiple pathogenic autoantibodies was reduced, although peptide-specific cytokine production and proliferation were not grossly changed.
The PLP tolerance experiment measured a different outcome. Palmitoylated PLP(139-151) reduced lymphocyte proliferation, while combining PLP(139-151) with PLP(178-191) produced a stronger effect in the experimental setting where the second determinant had become relevant.
These findings show that antigen-specific tolerance experiments can produce different measurable changes depending on the peptide, autoimmune model, and endpoint selected by the investigators.
What Limits Antigen-Specific Peptide Research?
MHC background is one documented limitation. MOG peptide studies found different recognition patterns across H-2 backgrounds, while the MOG(119-132) study found that the peptide was encephalitogenic in H-2^b strains but not in several non-H-2^b strains.
A second limitation is that a single self antigen can contain several experimentally relevant sequences. MOG studies identified multiple T-cell determinants, while lupus investigations identified several histone epitopes in both mouse and human systems.
A third limitation is that changing one amino acid can produce different responses among T-cell populations. PLP experiments found distinct recognition patterns among Th1 and Th2 clones exposed to related peptide sequences.
A fourth limitation is model dependence. Active and passive EAE produced different epitope-spreading patterns in the MBP experiments, showing that the method used to establish the autoimmune response can affect the subsequent antigenic repertoire.
Finally, tolerance findings also vary between experimental systems. Nucleosomal peptide studies measured regulatory T-cell responses and altered autoimmune T-cell help, while PLP studies measured lymphocyte proliferation and responses to separate myelin determinants. These differences make it inappropriate to treat results from one peptide or model as representative of all antigen-specific autoimmune responses.
Research Collection
Explore the peptide research collection from Direct SARMs for laboratory research information on available research compounds.
FAQs
References
- Franco A, Southwood S, Arrhenius T, Kuchroo VK, Grey HM, Sette A, Ishioka GY. T cell receptor antagonist peptides are highly effective inhibitors of experimental allergic encephalomyelitis. Eur J Immunol. 1994 Apr;24(4):940-6. PubMed β
- McRae BL, Nikcevich KM, Karpus WJ, Hurst SD, Miller SD. Differential recognition of peptide analogs by naive verses activated PLP 139-151-specific CD4+ T cells. J Neuroimmunol. 1995 Jul;60(1-2):17-28. PubMed β
- Das MP, Nicholson LB, Greer JM, Kuchroo VK. Autopathogenic T helper cell type 1 (Th1) and protective Th2 clones differ in their recognition of the autoantigenic peptide of myelin proteolipid protein. J Exp Med. 1997 Sep 15;186(6):867-76. PubMed β
- Voskuhl RR, Farris RW 2nd, Nagasato K, McFarland HF, Dalcq MD. Epitope spreading occurs in active but not passive EAE induced by myelin basic protein. J Neuroimmunol. 1996 Nov;70(2):103-11. PubMed β
- Yu M, Johnson JM, Tuohy VK. A predictable sequential determinant spreading cascade invariably accompanies progression of experimental autoimmune encephalomyelitis: a basis for peptide-specific therapy after onset of clinical disease. J Exp Med. 1996 Apr 1;183(4):1777-88. PubMed β
- Lu L, Kaliyaperumal A, Boumpas DT, Datta SK. Major peptide autoepitopes for nucleosome-specific T cells of human lupus. J Clin Invest. 1999 Aug;104(3):345-55. PubMed β
- Li Y, Huang Y, Lue J, Quandt JA, Martin R, Mariuzza RA. Structure of a human autoimmune TCR bound to a myelin basic protein self-peptide and a multiple sclerosis-associated MHC class II molecule. EMBO J. 2005 Sep 7;24(17):2968-79. PubMed β